Results 221 to 230 of about 19,015 (246)

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Journal of Diabetes, Volume 18, Issue 2, February 2026.
Network meta‐analysis comparing the effects of tirzepatide, semaglutide, and placebo on body weight reduction and glycemic outcomes in adults with overweight or obesity. ABSTRACT Introduction Pharmacological therapies are recommended for individuals with obesity.
Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca   +7 more
wiley   +1 more source

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation. [PDF]

Medicine (Baltimore)
Alansari AO, Alharbi AS, Alshehri KM, Alhabib AT, Alsalmi BS, Almosfer WA, AlAjlan FA, Alharbi AA, Alzahrani BS, Alamer B, Alatawi AM.   +10 more
europepmc   +1 more source

Hevin Promotes Aging‐Related Cardiac Dysfunction via Facilitating Cardiac Inflammation in Male Mice

Aging Cell, Volume 25, Issue 2, February 2026.
Hevin released by iWAT into circulation stimulates cardiac macrophages through TLR4, inducing their polarization and CCL5 secretion, leading to worsened cardiac dysfunction and subsequent recruitment of additional inflammatory cells for pro‐inflammatory factor release.
Shi‐Yu Huang, Yu‐Jie Chen, Yu‐Xin Hu, Jia‐Chen Liu, Min Hu   +4 more
wiley   +1 more source

Is Bariatric Surgery at Risk Due to Semaglutide? [PDF]

J Metab Bariatr Surg
Tian J, Bhatia S, Sneed C, Kiarie P, Fuchs M, Miele A, Shah D, Khan N, Louis MA.   +8 more
europepmc   +1 more source

Association Between Metabolic Syndrome, Obesity, and Cognitive Performances in Individuals With Bipolar Disorders: Cross‐Sectional and Longitudinal Analyses in the FACE‐BD Cohort

Acta Psychiatrica Scandinavica, Volume 153, Issue 2, Page 108-121, February 2026.
ABSTRACT Introduction Metabolic syndrome (MetS) has been suggested to be associated with cognitive impairments in bipolar disorder (BD); however, studies are limited by small sample sizes or cross‐sectional design. Our objective is to evaluate the cross‐sectional and longitudinal associations between MetS and cognitive performances in a large cohort of
I. Palimaru, B. Etain, M. Leboyer, Y. Dansou, P. Favre, S. Gard, V. Aubin, F. Bellivier, R. Belzeaux, P. Courtet, C. Dubertret, E. Haffen, A. Lefrere, P. M. Llorca, E. Olié, M. Polosan, L. Samalin, R. Schwan, the FondaMental Academic Centers of Expertise in Bipolar Disorders (FACE‐BD) Collaborators, B. Etain, E. Olié, M. Leboyer, E. Haffen, P. M. Llorca, V. Barteau, S. Bensalem, O. Godin, H. Laouamri, K. Souryis, S. Hotier, A. Pelletier, F. Hergeta, J. Petrucci, L. Willaume, F. Bellivier, B. Etain, V. Hennion, E. Marlinge, J. Meheust, A. Richard, M. Carminati, H. Francisque, S. Gard, K. M’Bailara, C. Elkael, F. Hoorelbeke, I. Minois, J. Sportich, N. Da Ros, C. Dubertret, N. Mazer, C. Portalier, C. Scognamiglio, A. Bing, P. Laurent, L. Boukhobza, P. Courtet, S. Denat, B. Deffinis, D. Ducasse, M. Gachet, A. Lengvenyté, F. Molière, L. Nass, E. Olié, G. Tarquini, A. Lefrere, E. Moreau, J. Pastol, F. Groppi, H. Polomeni, J. Bauberg, L. Lescalier, I. Muraccioli, A. Suray, R. Cohen, J. P. Kahn, M. Milazzo, O. Wajsbrot‐Elgrabli, T. Bougerol, A. Pouchon, A. Bertrand, B. Fredembach, A. Suisse, Q. Denoual, M. Polosan, A. M. Galliot, L. Brehon, G. Bonny, L. Durand, V. Feuga, N. Kayser, P. Roux, V. Aubin, I. Cussac, M. A. Dupont, J. Loftus, I. Medecin, C. Dubertret, N. Mazer, P. Laurent, L. Samalin, P. M. Llorca, M. Mennetrier, T. Bonnet, D. Lacelle, M. Vayssié, C. Beal, O. Blanc, P. Roux, O. Godin   +110 more
wiley   +1 more source

Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials. [PDF]

Cardiovasc Diabetol
Peng ZY, Lee YH, Ou HT, Kuo S.
europepmc   +1 more source

Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 396-404, February 2026.
This study investigated multiple non‐invasive tests (NIT) in a phase 2b study of patients with MASH and fibrosis treated with semaglutide. Findings revealed that semaglutide significantly improved NIT scores versus placebo from as early as 28 weeks. The results support the use of NITs to assess a treatment response to semaglutide.
Louise Maymann Nitze, Vlad Ratziu, Arun J. Sanyal, Vincent Wai‐Sun Wong, Clare Balendran, Jan Fleckner, Mette Skalshøi Kjær, Niels Krarup, Quentin M. Anstee   +8 more
wiley   +1 more source

Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report. [PDF]

BJPsych Open
Liekens L, Kaïret K, Elst EF.
europepmc   +1 more source

A Review of the Management of Obesity in Primary Care

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT This review highlights the important role primary care plays in obesity management, using England as an example. It includes a comprehensive summary of current management and referral options for primary care clinicians, a discussion of the most up‐to‐date clinical guidelines for the use of GLP‐1 receptor agonists in England, and the evolving ...
H. M. Parretti, S. E. Erskine, K. D. Coulman, R. Mears, K. Clare, K. Williamson, R. Watkins, C. A. Hughes   +7 more
wiley   +1 more source

Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information‐Based Mapping Exercises Across the 42 Integrated Care Boards of England

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level.
Anne de Bray, Hanna Schnitzer, Elisabeth Mahase, Puspha Singh, Rob Andrews, Barbara M. McGowan, Sarah Le Brocq, John P. H. Wilding, Stuart W. Flint, Jonathan M. Hazlehurst   +9 more
wiley   +1 more source